Two medications that bind potassium in the gastrointestinal tract are indicated for hyperkalemia management. Patiromer and sodium zirconium cyclosilicate have been studied in patients with chronic kidney disease, diabetes, and heart failure. Recent studies have examined the role of potassium binders as maintenance therapy to control hyperkalemia in high-risk patients.
In Brief:
Two medications that bind potassium in the gastrointestinal tract are indicated for hyperkalemia management. Patiromer and sodium zirconium cyclosilicate have been studied in patients with chronic kidney disease, diabetes, and heart failure. Recent studies have examined the role of potassium binders as maintenance therapy to control hyperkalemia in high-risk patients.
Go to Full Text of this Article